Latest Press Releases

Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma

December 20, 2022

Read More at Our Investor Site

Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform

December 12, 2022

Read More at Our Investor Site

Additional Resources


Receive Email Alerts

Media Contact

Melissa Downs

Senior Director, Corporate Communications
646-975-2533

media@lantheus.com

Investors

Mark Kinarney

Vice President, Investor Relations
978-671-8842

ir@lantheus.com